Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report |
| |
Authors: | Shu-Yan He Qing-Feng Lin Jie Chen Gui-Ping Yu Jun-Ling Zhang Dong Shen |
| |
Institution: | Shu-Yan He, Qing-Feng Lin, Jie Chen, Dong Shen, Department of Medical Oncology, The Jiangyin Clinical College of Xuzhou Medical University, Jiangyin 214400, Jiangsu Province, ChinaGui-Ping Yu, Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of Southeast University, Jiangyin 214400, Jiangsu Province, ChinaJun-Ling Zhang, Medical Department, 3D Medicines Inc., Shanghai 201114, China |
| |
Abstract: | BACKGROUNDThe most common EGFR mutations are in-frame deletions in exon 19 and point mutations in exon 21. Cases with classical EGFR mutations show a good response to EGFR tyrosine kinase inhibitors (TKIs), the standard first-line treatment. With the development of next generation sequencing, some uncommon genomic mutations have been detected. However, the effect of TKIs on such uncommon EGFR mutations remains unclear.CASE SUMMARYHere, we report a case of rare EGFR co-mutation in non-small cell lung cancer and the efficacy of afatinib on this EGFR co-mutation. A 64-year-old woman was diagnosed with thoracolumbar and bilateral local rib bone metastases, bilateral pulmonary nodules, and pericardial and left pleural effusion. The pathological diagnosis was lung adenocarcinoma. To seek potential therapeutic regimens, rare co-mutation comprising rare EGFR G724S/R776H mutations and amplification were identified. The patient experienced a significant clinical response with a progression-free survival of 17 mo. CONCLUSIONA case of non-small cell lung cancer with rare EGFR G724S/R776H mutations and EGFR amplification responds well to TKI treatment. |
| |
Keywords: | EGFR G724S and R776H Afatinib Non-small cell lung cancer Case report |
本文献已被 维普 等数据库收录! |
| 点击此处可从《》浏览原始摘要信息 |
|